Finance Watch: Exscientia Launches Last IPO Of Q3, Brings US Total To 88
AI-Enabled Firm Raised $464.7m From IPO, Private Placement
Executive Summary
Public Company Edition: Also, Roivant and two other biopharma firms close SPAC mergers and begin trading on the Nasdaq, Spero negotiated a royalty financing worth up to $125m and Phathom secured a $200m term loan.
You may also be interested in...
Exscientia And Sanofi Will Search For 15 Novel Oncology, Immunology Drugs Under New Pact
Building on an alliance dating back to 2016, Exscientia and Sanofi will use artificial intelligence and insights gleaned from patient tissue samples to seek out 15 novel therapies.
Finance Watch: 2021 Is Now Two Away From 100 Biopharma IPOs
Public Company Edition: Entrada’s initial public offering grossed $181.5m while Aura raised $75.6m and Biofrontera brought in $18m. Also, AnaptysBio received $250m in Jemperli royalty deal and 4D Molecular Therapeutics grossed $118.8m in a follow-on offering.
MoonLake Takes SPAC Route To Challenge Novartis's Cosentyx
MoonLake of Switzerland is heading to the NASDAQ armed with $230m to take its tri-specific IL17A/IL-17F nanobody sonelokimab, acquired from Merck KGaA, into the highly competitive spaces of psoriatic arthritis, ankylosing spondylitis and hidradenitis suppurativa.